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Maria Inês Almeida1,2* and George Adrian Calin3,4Editorial summary
miR-143 and miR-145 have been widely described as
tumor suppressors. Recent findings suggest these
microRNAs (miRNAs) have a critical role that affects
the stroma rather than epithelial cells. Understanding
the part played by the miR-143/miR-145 cluster in the
tumor microenvironment is essential for the
development of future miRNA-related therapies.a recent well-designed study performed by Dimitrova,Tumor suppression
The contribution of the microenvironment to promoting
tumor growth has been recognized for decades [1]. Im-
mune cells, fibroblasts, endothelial cells, mesenchymal
stem cells, pericytes and, in some cases, adipocytes, are
among the cell types that surround and interact with
tumor cells, forming the tumor microenvironment [1]. A
tumor generates a local response that leads to modifi-
cations of the extracellular matrix at the molecular,
biological and mechanical levels, which in turn sup-
ports tumor growth and migration [1]. The surround-
ing cells secrete a cocktail of tumor-promoting factors,
including cytokines, chemokines, pro-angiogenic and
anti-inflammatory mediators, and extracellular vesicles,
which all play a part in stimulating tumor progression
[1]. Therefore, the cells present in the tumor stroma
should be considered when studying the underlying
biological mechanisms and therapeutic approaches for
epithelial tumors.
MicroRNAs (miRNAs) are small non-coding RNAs
that regulate gene expression at a post-transcriptional
level, inhibiting mRNA translation or degrading mRNA.
They are crucial players in tumorigenesis, and can act as
oncogenes or tumor suppressors [2]. One set of miRNAs* Correspondence: ines.almeida@ineb.up.pt
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cluster, which is formed by two co-transcribed but dis-
tinct miRNAs. This cluster has been described as having
tumor suppressive functions in several tumor types that
have an epithelial origin, such as cervical, colon, gastric,
breast and pancreatic carcinomas [3]. This has been
shown by miRNA expression analyses in tumor and nor-
mal tissue samples and in gain-of-function and loss-of-
function studies, both in vitro and in vivo [3]. However,
Gocheva and colleagues contradicts the concept of the
miR-143/miR-145 cluster as a classical tumor suppressor
[4]. miR-143 and miR-145 have been considered ideal
candidates for cancer therapy, and several strategies for
delivery of these miRNAs into cells are being explored
[3]. Therefore, this study has important implications.Tumor promotion
To explore the endogenous role of the miR-143/miR-
145 cluster, Dimitrova, Gocheva and colleagues initially
used mice with a conditional knockout for miR-143/
miR-145, but these animals failed to develop tumors,
and differences in survival between these mice and con-
trols were not detected [4]. Next, the researchers in-
duced tumor-specific deletion of miR-143/miR-145 in a
lung cancer mouse model (KrasG12D/+, p53–/–) in which
tumors resemble human lung tumors. However, no dif-
ferences in tumor burden or survival rate were found. In
the same model, mice infected with a conditional lenti-
virus vector for forced expression of either miR-143 or
miR-145 showed no difference in tumor burden when
compared with controls. These results contradict earlier
suggestions that the miR-143/miR-145 cluster has a
tumor suppressor role [4]. Surprisingly, in the lung can-
cer mouse model, animals with a miR-143/miR-145
knockout (an organism-wide deletion) showed decreased
number of tumors and reduced tumor area compared
with controls. The same effect was also present after
mice tail vein injection of KrasG12D/+, p53–/– cells with
miR-143/miR-145 null alleles. Altogether, these resultsarticle is distributed under the terms of the Creative Commons Attribution 4.0
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could support tumor growth and launched the hypoth-
esis that these miRNAs affected the stroma rather than
epithelial cells [4].
To further explore the role of the tumor microenvir-
onment, stromal cells were isolated and sorted, and the
researchers found that endothelial cells, but not epithe-
lial cells, were enriched in miR-143/miR-145. In miR-
143/miR-145-deficient mice, active neoangiogenesis was
reduced, and this effect could be partially explained by
miRNA targeting of calcium/calmodulin dependent
protein kinase ID (Camk1d), a protein involved in angio-
genesis [4]. Specifically, miR-145 binds to the 3’ untrans-
lated region (UTR) of Camk1d and represses its
expression. This study points to the miR-143/miR-145
cluster as a critical promoter of neoangiogenesis [4].
This finding is of crucial importance, as gain-of-function
therapeutic strategies using this cluster could promote
neoangiogenesis in the lung cancer microenvironment
and support tumor growth instead of suppressing it.
This is the second in vivo study arguing against a
tumor-suppressor function for the miR-143/miR-145
cluster [5]. Although exogenous forced-expression stud-
ies had suggested that the miR-143/miR-145 cluster is a
tumor suppressor in colorectal cancer, Chivukula, Shi
and collaborators studied the role of these miRNAs in
intestinal physiology and failed to detect abnormalities
in the development or architecture of the small and
large intestine in miR-143/miR-145-deficient mice [5].
However, these mice could not recover from intestinal
injury. Moreover, these researchers detected miR-143
and miR-145 in mesenchymal cells but not in epithelial
cells of the intestine [5]. Together, these results suggests
that the stromal microenvironment is regulated by these
miRNAs rather than the intestinal epithelium. Depletion
of miR-143 and miR-145 caused dysfunction of smooth
muscle cells and myofibroblasts, which in turn impaired
the regeneration of the intestinal epithelium. This effect
was explained, at least in part, by miR-143 targeting of
insulin-like growth factor binding protein 5 (IGFBP5),
which in turn negatively regulates the insulin-like growth
factor signaling pathway, known to be critical for intestinal
epithelial proliferation [5].
In the majority of gene expression studies in cancer,
RNA is isolated from heterogeneous tumor samples.
This approach can generate misleading conclusions, as
expression of a miRNA exclusively in one specific cell
type can appear as bulk expression [6]. Therefore, when
studying gene expression levels in epithelial tumor cells,
the stromal bias should be considered. Analysis of gene
expression levels after fluorescence-activated cell sorting
for distinct cell populations could overcome this issue
[4]. Another approach could be the use of laser capture
microdissection, which enables single cell isolation basedon morphology or presence or absence of cell markers
[7]. Finally, in situ hybridization could also be used to
determine expression of miRNAs in specific cell types
and their location within the tissue sample [8].
Delivery of exogenous miRNAs is considered as one of
the most promising novel strategies for treatment of
human cancer [9]. However, it is important to consider
the endogenous expression and the effects of miRNAs
in vivo on the tumor microenvironment, as elegantly
revealed by Dimitrova, Gocheva and collaborators [4].
Therefore, care should be taken when selecting miRNAs
for exogenous therapeutic delivery. A direct-targeting
system specific for tumor cells is essential to avoid ex-
posure of the tumor microenvironment to treatment.
Some miRNAs might cause apoptosis and reduce prolif-
eration of tumor epithelial cells but at the same time
increase pro-tumorigenic mediators secreted by stromal
cells. Moreover, the number and type of stromal cells
present in the tumor microenvironment might differ in
respect to the tumor type. Therefore, the expression and
effects of miRNAs in the stroma should be dissected in
every type of tumor and the potential of miRNA com-
munication through miRNA secretion in the microenvir-
onment should be tested. This type of communication
was shown, for example, for miR-21, which is secreted
by epithelial malignant cells and induces the release of
miR-155 by monocytes; miR-155 is then transferred to
the same epithelial cells and induces resistance to ther-
apy [10]. The interplay between malignant cells and the
microenvironment is more complicated than initially
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